Abstract:Since the discovery of Coxsackie group of viruses by Dalldorf and Sickles(l), it has been known that viruses of this group are found not only in the United States of America but also widely distributed all over the world. In this respect, it is considered to be very interesting to report on some information of how the viruses of this group are distributed in Japan. First, the distribution of antibodies against several members of the viruses in this group was elucidated. The detection of the antibodies was performed by means of virus neutralization reaction and complement fixation reaction using the strains T.T. (Group A type 1 of Dalldorf's classification (2)) , Fleetwood (Group A type 2), J.Ol. (Group A type 3) and P.O. (Group B type 1). In neutralization reaction, 5 times diluted human serum was added to the serial 10-fold dilution of virus suspension, and thus after 30 minutes' stillstand at room temperature, inoculation was made into suckling mice. After ten days' observation, the inf ectivity index was compared between serum-added group and control group. If inf ectivity index was reduced to one tenth of the value of the control by addition of human serum, the neutralizing capacity of the serum under test was designated as +, if reduced to one hundredth, if, and if reduced to one thousandth, tlt. For instance, provided the infectivity index value of the control mouse group was 10-7.3, and this value was reduced, say, to 10-5.4 by addition of human serum, the neutralizing capacity of this serum was designated as ft. In complement fixation reaction, the technique which was utilized by Brown(3) for diagnosis of encephalitis was followed. Methanol precipitation method was employed mostly in the preparation of the antigen for complement fixation reaction but ultracentrifugation method was also used. In the methanol precipitation, 30% methanol was used and elution was made with M/10 phosphate buffer of pH 8.0. pH 9.0 was not used for elution because, at this pH value, though the yield of antigenic substance was at its best, anticomplementary substances were also eluted and disturbed the reaction. The serum was taken from those healthy adults who were working in our institute in Tokyo. The result of the examination of these sera was summarized in Table 1. As seen in the table, some of them contained antibodies more or less

Minimax approximate solutions of linear boundary value problems

Field evaluation of a sing‐dose bivalent vaccine of porcine circovirus type 2b and Mycoplasma hyopneumoniae

Efficacy of a novel bivalent vaccine containing porcine circovirus type 2d and Mycoplasma hyopneumoniae against a dual PCV2d and Mycoplasma hyopneumoniae challenge

A Comparative Field Evaluation of the Effect of Growth Performance Between Porcine Circovirus Type 2a (PCV2a)- and PCV2b-Based Bivalent Vaccines Containing PCV2 and Mycoplasma hyopneumoniae

Efficacy Evaluation of a Bivalent Vaccine Containing Porcine Circovirus Type 2b and Mycoplasma hyopneumoniae Against an Experimental Dual Challenge

Comparative Evaluation of Growth Performance between Bivalent and Trivalent Vaccines Containing Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae in a Herd with Subclinical PCV2d Infection and Enzootic Pneumonia

Efficacy of bivalent vaccines of porcine circovirus type 2 and Mycoplasma hyopneumoniae in specific pathogen-free pigs challenged with porcine circovirus type 2d

Distribution of the Coxsackie group of viruses in Japan.

Cross-protection of a porcine circovirus types 2a/b (PCV-2a/b) and Mycoplasma hyopneumoniae trivalent vaccine against a dual PCV-2e and Mycoplasma hyopneumoniae challenge

Efficacy Studies of a Trivalent Vaccine Containing PCV-2a, PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Days of Age and 3 Weeks Later against Porcine Circovirus 2 (PCV-2) Infection

A porcine circovirus type 2d-based virus-like particle vaccine induces humoral and cellular immune responses and effectively protects pigs against PCV2d challenge

Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2

Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age

A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and porcine Circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs

Field efficacy of a novel porcine reproductive and respiratory syndrome modified-live virus vaccine with an emphasis on growth performance

One Dose of a Novel Vaccine Containing Two Genotypes of Porcine Circovirus (PCV2a and PCV2b) and Mycoplasma hyopneumoniae Conferred a Duration of Immunity of 23 Weeks

A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccine

Studies on porcine circovirus type 2 vaccination of 5-day-old piglets

A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions

Effectiveness of two intramuscular combined vaccines for the control of Mycoplasma hyopneumoniae and porcine circovirus type 2 in growing pigs: a randomized field trial

Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm